| __timestamp | Agios Pharmaceuticals, Inc. | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 12665000 |
| Thursday, January 1, 2015 | 141827000 | 20202000 |
| Friday, January 1, 2016 | 220163000 | 32407000 |
| Sunday, January 1, 2017 | 292681000 | 35219000 |
| Monday, January 1, 2018 | 1397000 | 36386000 |
| Tuesday, January 1, 2019 | 1317000 | 43081000 |
| Wednesday, January 1, 2020 | 2805000 | 39330000 |
| Friday, January 1, 2021 | 18777000 | 43283000 |
| Saturday, January 1, 2022 | 1704000 | 48316000 |
| Sunday, January 1, 2023 | 9504000 | 54634000 |
| Monday, January 1, 2024 | 4165000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology and medical devices, understanding cost dynamics is crucial. From 2014 to 2023, Agios Pharmaceuticals, Inc. and MiMedx Group, Inc. have shown contrasting trends in their cost of revenue. Agios Pharmaceuticals experienced a significant fluctuation, peaking in 2017 with a cost of revenue nearly 300% higher than its 2014 value. However, post-2017, Agios saw a dramatic decline, with costs dropping by over 95% by 2022, before a slight recovery in 2023.
Conversely, MiMedx Group, Inc. demonstrated a steady increase, with costs rising by approximately 330% over the same period. This consistent growth reflects MiMedx's expanding operations and market presence. The data highlights the strategic shifts and market challenges faced by these companies, offering valuable insights for investors and industry analysts.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.
Viatris Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc.
Jazz Pharmaceuticals plc vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Analyzing Cost of Revenue: Pharming Group N.V. and MiMedx Group, Inc.
Cost of Revenue Comparison: Cytokinetics, Incorporated vs MiMedx Group, Inc.
Cost of Revenue Comparison: Ionis Pharmaceuticals, Inc. vs MiMedx Group, Inc.
Cost of Revenue Trends: Perrigo Company plc vs MiMedx Group, Inc.
Agios Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Agios Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.